Session#	Session Title	UAN	Activity Type	PDU#
104	Reporting of Pre-Market and Post-Market Safety Reports to FDA Adverse Event Reporting System (FAERS) Using ICH E2B R3 Standards	0286-0000-24-518-L04-P	Knowledge	
105	The Intersection of Science, Ethics, and Participant Collaboration in Pediatric Rare Disease Product Development	0286-0000-24-519-L04-P	Knowledge	
106	Machine Learning and Simulations to Facilitate Clinical Trials	0286-0000-24-520-L04-P	Knowledge	
107	Cloud-Driven Transformation: Empowering Pharma Industry and Regulators	0286-0000-24-521-L04-P	Knowledge	
108	Risk Management in Advanced Device Technology Development	0286-0000-24-522-L04-P	Knowledge	
109	GCP Renovation: How Will GCP Inspection Change in Europe, Japan, and the US?	0286-0000-24-523-L04-P	Knowledge	
110	Modernizing CDER's New Drugs Review Program (NDRP): A Progress Update	0286-0000-24-524-L04-P	Knowledge	
111	China Town Hall	0286-0000-24-525-L04-P	Knowledge	
112	Regulatory Convergence for CMC Requirements: The Challenges and Benefits of a Single Global Dossier	0286-0000-24-526-L04-P	Knowledge	
113	Master Protocols: Integrating and Debating Clinical Trial Designs	0286-0000-24-527-L04-P	Knowledge	
114	Breaking Boundaries: Overcoming Policy Crosstalk and Globalization Barriers to Foster Innovation	0286-0000-24-528-L04-P	Knowledge	
116	Navigating the Trusted, Responsible, and Ethical Horizon of Artificial Intelligence: Uniting Healthcare Perspectives	0286-0000-24-529-L04-P	Knowledge	
130	Interactive Safety Graphics in the Regulatory Decision-Making Process	0286-0000-24-530-L04-P	Knowledge	
131	Innovative Approaches to the Design of Pediatric Development Programs: What's New in the Use of Pediatric Extrapolation	0286-0000-24-531-L04-P	Knowledge	

132	The Cost of Moving the Needle on Clinical Trial Representation: Strategies for Diversity Budget Planning and Resourcing	0286-0000-24-532-L04-P	Knowledge	
133	ICH M11 Protocol Template: A Global Solution for Global Drug Development	0286-0000-24-533-L04-P	Knowledge	
134	Shifting Medical Writing Value Propositions with the Use of Technology Tools	0286-0000-24-534-L04-P	Knowledge	
135	Enhancing the Science of Patient Engagement and Patient Input: What's in the Future?	0286-0000-24-535-L04-P	Knowledge	
136	In Vitro Diagnostic/Companion Diagnostics Developments in the US and Impact on Global Programs	0286-0000-24-536-L04-P	Knowledge	
137	Options to Consider When Balancing Risk, Timelines, Cost, and Patient Centricity While Meeting Project Optimus Guidelines	0286-0000-24-537-L04-P	Knowledge	2166YE3LVS
138	Having the End in Mind When Building Quality into Clinical Trials: A Regulatory and Industry Perspective	0286-0000-24-538-L04-P	Knowledge	
139	Comparative Perspectives on Regulating AI in Drug Development: US Versus EU	0286-0000-24-539-L04-P	Knowledge	
140	The State of Real-World Evidence for Regulatory Decision-Making: Views from FDA, EMA, and PMDA	0286-0000-24-540-L04-P	Knowledge	
141	Innovation in Manufacturing Globally	0286-0000-24-541-L04-P	Knowledge	
142	Causal Inference Methodology in Drug Development	0286-0000-24-542-L04-P	Knowledge	
144	Paradigm Shift in Adverse Event Report Management and Sharing: The Case, The Need, and Possible Ways Forward	0286-0000-24-543-L04-P	Knowledge	
145	Selective Safety Data Collection: As a Tool to Advance Clinical Trial Designs	0286-0000-24-544-L04-P	Knowledge	
146	Past, Present, and Future: How Industry and FDA are Handling the Evolving Clinical Trial Diversity Regulatory Landscape	0286-0000-24-545-L04-P	Knowledge	
147	Data and Technology Influence on ICH Initiatives: M4Q(r2)/Q12 and Global Harmonization	0286-0000-24-546-L04-P	Knowledge	
148	Navigating the Regulatory Landscape: Real-World Data and Real-World Evidence in Regulatory Documents	0286-0000-24-547-L04-P	Application	
149	Effective Patient / Industry Collaboration: Valuing Patient Lived Experience To Inform Trial Design	0286-0000-24-548-L04-P	Knowledge	
150	Building Trust in New Alternative Methods in Investigational New Drug Applications	0286-0000-24-549-L04-P	Application	
151	Elevate Leadership: Harnessing the Five Superpowers	0286-0000-24-550-L04-P	Knowledge	2166LI6KQZ
152	Innovative Alternative Approaches to Evaluating GCP During the COVID-19 Public Health Emergency and Beyond	0286-0000-24-551-L04-P	Knowledge	

153	Designing your Regulatory Intelligence Framework: Powered by Artificial Intelligence and Critical Thinking	0286-0000-24-552-L04-P	Knowledge
154	Impact of Accelerated Pathways on Patients in Five Countries/Regions	0286-0000-24-553-L04-P	Knowledge
155	Health Canada Town Hall	0286-0000-24-554-L04-P	Knowledge
156	Data Insight Generation: Leveraging Data Visualization in Study Planning, Monitoring, Exploration, Reporting, and Submission	0286-0000-24-555-L04-P	Knowledge
201	Considerations for Identification of Drug-Induced Liver Injury	0286-0000-24-556-L04-P	Knowledge
202	Behavioral and Educational Strategies for Avoiding Falsified Medicine Exposure (BE SAFE)	0286-0000-24-557-L04-P	Knowledge
203	Feasible Site Feasibility Assessments: Rethinking Business as Usual to Reduce Burden, Timelines, and Costs for Sustainability	0286-0000-24-558-L04-P	Knowledge
204	Wearable Sensors and Digital Health Technologies for Tracking Neurological and Neuromuscular Disorders	0286-0000-24-559-L04-P	Knowledge
205	Data Standards SOS: Reducing Burnout and Navigating Through Fatigue - Part 1	0286-0000-24-560-L04-P	Knowledge
206	Early Engagement to Enhance the Incorporation of Patient Experience Data in Drug Development Programs and Regulatory Decision-Making	0286-0000-24-561-L04-P	Knowledge
207	Early Experience with EU In Vitro Diagnostics Regulation: Performance Study Applications	0286-0000-24-562-L04-P	Knowledge
208	Good Data Governance Practices: Regulatory and Industry Perspectives	0286-0000-24-563-L04-P	Knowledge
209	Leveraging New Meeting Opportunities in PDUFA VII: Experiences with Type D and INTERACT	0286-0000-24-564-L04-P	Knowledge
210	Digital Biomarkers as Clinical Endpoints: The Road to Regulatory Acceptability	0286-0000-24-565-L04-P	Knowledge
211	PMDA Town Hall	0286-0000-24-566-L04-P	Knowledge
212	Supporting Regulatory Convergence and Reliance Through a Pharmaceutical Quality Knowledge Management Capability	0286-0000-24-567-L04-P	Knowledge
213	Beyond Traditional Trials: Real-World Data for External Controls, with Focus on Cancer Drug Applications	0286-0000-24-568-L04-P	Knowledge
218	Long-Term Safety of Approved Medicines: Approaches for Identifying, Characterizing, and Quantifying Delayed Adverse Events	0286-0000-24-569-L04-P	Knowledge
219	How to Compare FDA Medical Queries and Standardized MedDRA Queries with Interactive Graphics	0286-0000-24-570-L04-P	Knowledge
220	Targeting Shared Molecular Etiologies to Accelerate Drug Development for Rare Diseases	0286-0000-24-571-L04-P	Knowledge

221	Improving Patient Access to Clinical Trials Through Decentralization and Flexible Design: Lessons from Oncology	0286-0000-24-572-L04-P	Knowledge
222	External Control Arms at Scale: Multicenter, Multisource Infrastructure for External Control Arms	0286-0000-24-573-L04-P	Knowledge
223	Challenges in Exceeding the Quality of Existing Endpoints and Approaches Using Digital Tools	0286-0000-24-574-L04-P	Knowledge
224	Data Standards SOS: Reducing Burnout and Navigating through Fatigue - Part 2	0286-0000-24-575-L04-P	Knowledge
225	Regulatory Guidance and Papers on Technology Innovations	0286-0000-24-576-L04-P	Knowledge
226	Effective Patient Engagement in Patient Experience Data: Practical Insights from Case Studies in Hard-to-Reach Populations	0286-0000-24-577-L04-P	Application
227	How to Ensure Compliance in a Changing Regulatory Environment: A Regulators Perspective	0286-0000-24-578-L04-P	Knowledge
228	Access Consortium and Project Orbis: Experiences from Industry and Regulatory Authorities and Recommendations for Improvement	0286-0000-24-579-L04-P	Knowledge
229	Clinical Trial Enrollment Diversity: Why and How to Engage Community Health Centers	0286-0000-24-580-L04-P	Knowledge
230	International Regulatory Convergence: Regulatory Science to Address Challenges Brought by Pharmaceutical Innovation	0286-0000-24-581-L04-P	Knowledge
244	Evidence Generation to Support Regulatory Decision-Making: Shift of the Trend over Time	0286-0000-24-582-L04-P	Knowledge
245	The European Clinical Trials Environment Under the Accelerating Clinical Trials (ACT EU) Initiative: Two Years On	0286-0000-24-583-L04-P	Knowledge
246	The State of Clinical Trials in 2024: Are We Making the Grade?	0286-0000-24-584-L04-P	Knowledge
247	Bridging Randomized Clinical Trials and Real-World Data Utilizing Data Linkage and Tokenization	0286-0000-24-585-L04-P	Knowledge
248	The Evolving Role of Artificial Intelligence in the Medicinal Product Lifecycle	0286-0000-24-586-L04-P	Knowledge
249	Topics Related to the Oncology Real-Time Oncology Review Process	0286-0000-24-587-L04-P	Knowledge
250	Implementable Approaches to Fully Integrating Patient Engagement Across an Entire Company: Including all Clinical Trials	0286-0000-24-588-L04-P	Knowledge
251	Enabling Patient Access Worldwide Including Japan or Other Countries to Innovative Drugs Through Global Development Strategy	0286-0000-24-589-L04-P	Knowledge

252	Ensuring Inspection Readiness for Clinical Trials Using Decentralized Clinical Trial Design Features	0286-0000-24-590-L04-P	Knowledge	
253	Platform Technology Designation: Opportunities and Challenges for Implementation	0286-0000-24-591-L04-P	Knowledge	
254	FDA Rare Disease Town Hall	0286-0000-24-593-L04-P	Knowledge	
255	International Harmonization to Support Pharmaceutical Quality and Lifecycle Management	0286-0000-24-594-L04-P	Application	
263	Risk Management Planning- Some Twenty Years Later: Where we Started, How Far we have Come and a Modern Path Forward	0286-0000-24-595-L04-P	Knowledge	
264	Advancing Innovation in Clinical Trial Design and Conduct	0286-0000-24-596-L04-P	Knowledge	
265	Practical Approaches and Resources to Optimize Advocacy Group - Industry Collaborations: An Update on the PALADIN Consortium	0286-0000-24-597-L04-P	Knowledge	
266	Exploiting Real-World Data From Social Media in Patient-Focused Drug Development	0286-0000-24-692-L04-P	Knowledge	
267	Evolution of Electronic Product Information in LATAM: Challenges and Opportunities to Improve the Value of Healthcare	0286-0000-24-599-L04-P	Knowledge	
268	Strategies to Make your Clinical Trials More Inclusive for Patients with Disabilities	0286-0000-24-600-L04-P	Knowledge	
269	For Whom the Cell Tolls: Ethics in the Era of Precision Medicine	0286-0000-24-601-L04-P	Knowledge	
270	Something Borrowed Something New for Effective Project Management: Adopting Different Thinking Approaches and New Technologies in Life Science Project Management	0286-0000-24-602-L04-P	Application	2166XALVLX
271	How Will the Increasing use of Real-World Evidence for Regulatory Decision-Making Impact QA Strategies and GCP	0286-0000-24-603-L04-P	Knowledge	
272	This is Your Pilot Speaking: The Journey from Regulatory Pilot Program Innovation to Routine Practice	0286-0000-24-604-L04-P	Application	
273	How to Provide Necessary Medicinal Products to Children?	0286-0000-24-605-L04-P	Knowledge	
274	Regulatory Policy Roundtable: Pharmaceutical Quality, Generics, Innovative Medicines	0286-0000-24-606-L04-P	Knowledge	
275	Securing the Chain: US and EU Legislative Reforms and Regulatory Actions for Drug Shortage Mitigation	0286-0000-24-607-L04-P	Knowledge	
276	The Promise of Disease Progression Modeling to Bring Treatments to Patients Sooner	0286-0000-24-608-L04-P	Knowledge	
277	FDA's Approach in Harmonize Surveillance for Drugs and Biologics Safety and Quality Data	0286-0000-24-609-L04-P	Knowledge	

278	Regulatory, Pharmacoepidemiologic, and Pharmacovigilance Considerations Related to the Safety of Drugs Used During Pregnancy	0286-0000-24-610-L04-P	Knowledge	
279	Accelerating Innovation Through Design: Integrating Real-World Data into Clinical Trials	0286-0000-24-611-L04-P	Knowledge	
280	Innovation, Agility, and Accessibility in Trial Execution: Exploring the Roles, Pathways, and Potential for Integration of Embedded Clinics, Retail Pharmacies, and Diagnostic Providers in Clinical Research at Scale	0286-0000-24-693-L04-P	Knowledge	
281	Harnessing Real-World Evidence in Regulatory Decision-Making: Update on DARWIN EU, Use of Real-World Evidence in New Applications in the EU	0286-0000-24-613-L04-P	Knowledge	
282	Shame and Blame: Our Words are a Barrier to Clinical Research are a Care Option	0286-0000-24-614-L04-P	Knowledge	
283	The Value of Project Management in Driving Drug Discovery Success: A Comparison Between Small Versus Large Pharmaceutical Companies	0286-0000-24-615-L04-P	Knowledge	2166M3MMI2
284	Collaboration in an Expanding Regulatory Landscape for Pharmacovigilance	0286-0000-24-616-L04-P	Knowledge	
285	Remote Regulatory Assessments: Examining Another Tool in the FDA Regulatory Toolbox	0286-0000-24-617-L04-P	Knowledge	
286	Recent Evolution of Accelerated Approval Pathways: Impacts on the Pathways Use and Implementation	0286-0000-24-618-L04-P	Knowledge	
287	ANVISA Town Hall	0286-0000-24-619-L04-P	Knowledge	
289	Post-COVID cGMP Inspections by Global Regulatory Authorities	0286-0000-24-620-L04-P	Knowledge	
290	Charting the Biosimilars Beat Drop: The Latest Updates in the Biosimilars Landscape, Coverage, and Adoption in the US	0286-0000-24-621-L04-P	Knowledge	
301	Risk Minimization in the EU: New Guidance, New Collaborations	0286-0000-24-622-L04-P	Knowledge	
302	Have a Safe Trip: Clinical and Patient Alignment in Clinical Trials with Psychedelics	0286-0000-24-623-L04-P	Knowledge	
303	How Common Data Models Can Address the Challenges in the Use of Clinical Trial and Real-World Data for Evidence Generation	0286-0000-24-624-L04-P	Knowledge	
304	Synergizing Large Language Models and Digital Health Technology for Healthcare Transformation	0286-0000-24-625-L04-P	Knowledge	
305	All the Ways Medical Affairs Supports Product Development: From Clinical Trials to Product Launch	0286-0000-24-626-L04-P	Knowledge	
306	Which Clinical Outcome Assessment to Choose: Questionnaire or Sensor? Time to Align an Endpoint Selection Framework	0286-0000-24-627-L04-P	Knowledge	

307	Partnering with Regulatory Authorities to Unlock the Value in Digital Health Products	0286-0000-24-628-L04-P	Knowledge	
308	Unlocking Innovation: Implementing Future-Focused Risk-Based Quality Management Quality Briefs - A Cross-	0286-0000-24-629-L04-P	Application	
309	FDA Oncology Center of Excellence: Are Sponsors Taking Full Advantage of OCE Regulatory Policy “Projects?”	0286-0000-24-630-L04-P	Knowledge	
310	WHO Town Hall: Safeguarding Public Health - WHO's Vision for Global Regulatory Excellence	0286-0000-24-631-L04-P	Knowledge	
311	Australia, Canada, Singapore, Switzerland, and United Kingdom Consortium (Access): Re-Imagining Regulatory Collaboration	0286-0000-24-632-L04-P	Knowledge	
312	Revolutionizing Regulatory CMC and Advanced Manufacturing with the Power of AI: Unleashing Innovation and Efficiency	0286-0000-24-633-L04-P	Knowledge	
313	The Future of Women’s Health: Do We Really Want Innovation? Policy Ideas To Advance Innovation, Access, and Novel Approaches	0286-0000-24-634-L04-P	Knowledge	
317	Unlocking the Potential of Pharmacogenomics for Reducing the Burden of Adverse Drug Reactions	0286-0000-24-635-L04-P	Knowledge	
318	Defining an Inclusive Clinical Trials Approach in Europe	0286-0000-24-636-L04-P	Knowledge	
319	Unlocking the Potential of IDMP for Global Exchange of Medicinal Products Data	0286-0000-24-637-L04-P	Knowledge	
320	AI Process in Medical Writing, AI Utilization, and AI Real-World Use Cases	0286-0000-24-638-L04-P	Knowledge	
321	The ChatBot Will See You Now: Ethical Considerations in Incorporating AI into Informed Consent	0286-0000-24-639-L04-P	Knowledge	
322	Leveraging Testing Results Generated Within Treating Hospitals for Trials Across the Globe	0286-0000-24-640-L04-P	Knowledge	
323	Driving Capacity Building, Equity, and Geographic Expansion in Clinical Trials	0286-0000-24-641-L04-P	Knowledge	2166PJJJ85
324	Using Data Analytics for Good Pharmacovigilance Practices	0286-0000-24-642-L04-P	Application	
325	A Paradigm Shift in Global Regulatory Reviews: Has the New Normal Arrived?	0286-0000-24-643-L04-P	Knowledge	
326	Bringing Transformational Treatments to Patients: Regulatory Convergence and Reliance on Cell and Gene Therapy Products	0286-0000-24-644-L04-P	Knowledge	
327	Enabling Innovation and Regulatory Agility to Address Sustainability, Environment, and Climate Goals	0286-0000-24-645-L04-P	Knowledge	

328	Pioneering New Frontiers: Advanced Drug Delivery Technologies and Cell/Gene Therapies in Combination Products	0286-0000-24-646-L04-P	Application
344	Leveraging Point of Care Technologies for Near Real Time, Interactive Safety Surveillance: Opportunities and Challenges	0286-0000-24-647-L04-P	Knowledge
345	Regulatory Considerations in Trial Design for Cell and Gene Therapies	0286-0000-24-648-L04-P	Knowledge
346	A Clinical Research Workforce in Crisis: Imperatives for a Sustainable Staffing Model	0286-0000-24-649-L04-P	Knowledge
347	Artificial Intelligence in the Drug Development Lifecycle: Opportunities and Challenges in Regulatory Operations	0286-0000-24-650-L04-P	Knowledge
348	Challenges and Solutions to Building the Right Patient-Centered Evidence to Support Fit-For-Purpose Sensor-Based Outcomes	0286-0000-24-651-L04-P	Knowledge
349	Study Design for Cell and Gene Therapy Trials: Regulatory Overview, Challenges, and Updates	0286-0000-24-652-L04-P	Knowledge
350	ICH Efforts to Incorporate Patient's Perspective to Enhance Quality, Relevance, Safety and Efficacy of Drug Development	0286-0000-24-653-L04-P	Knowledge
351	Revolutionizing Quality Management: Harnessing the Power of AI for Enhanced Decision Making and Continuous Improvement	0286-0000-24-654-L04-P	Knowledge
352	Applying Machine Learning and Artificial intelligence for Predicting Product Profile Approvability (PoPPA)	0286-0000-24-655-L04-P	Application
353	ICH M15 Model Informed Drug Development: Steps Toward Harmonized Guidance	0286-0000-24-656-L04-P	Knowledge
354	ICMRA Post-Pandemic: Regulators Looking into the Future	0286-0000-24-657-L04-P	Knowledge
355	Unlocking the Puzzle of Borrowing Adult Data for Designing Innovative Hybrid Pediatric Trials	0286-0000-24-658-L04-P	Knowledge
359	A Safety Surveillance Plan for Serious Anticipated Events	0286-0000-24-659-L04-P	Knowledge
360	More than Meets the Eye: AI's Potential to Identify Skin Manifestations of Internal Disease in Patients of Color	0286-0000-24-660-L04-P	Knowledge
361	Recruitment Optimization in Clinical Trials: Looking Towards an Adaptive Future	0286-0000-24-661-L04-P	Knowledge
362	Streamlining Processes and Data Exchange Across R&D Functions to Improve Performance and Facilitate Automation	0286-0000-24-662-L04-P	Knowledge
363	Implementing Changes To Drug-Device Combination Products Globally	0286-0000-24-663-L04-P	Knowledge

364	Unlocking Success: Mastering the Pharmaceutical Asset Lifecycle Journey	0286-0000-24-664-L04-P	Knowledge	216658O27Z ~~21668FZSM7~~
365	Embedding Diversity and Inclusion into Global Clinical Research: Where Have we Been and Where are we Going?	0286-0000-24-665-L04-P	Knowledge	
366	The Intersection of Patient-Experience Data and Benefit-Risk Analysis	0286-0000-24-666-L04-P	Knowledge	
367	EMA Town Hall	0286-0000-24-667-L04-P	Knowledge	
368	Harnessing the Power of Artificial Intelligence (AI) in Clinical Research From Knowledge Graphs to Generative AI	0286-0000-24-668-L04-P	Knowledge	
370	Critical Appraisal of Artificial Intelligence Solutions for Pharmacovigilance	0286-0000-24-669-L04-P	Knowledge	
371	Using Influencers to Recruit Hard-to-Engage Populations	0286-0000-24-670-L04-P	Knowledge	
372	Leveraging Cloud-Based Technologies to Accelerate Reliance and Convergence: An Industry and Regulatory Agency Experience	0286-0000-24-671-L04-P	Knowledge	
373	Patient-Centric Approaches in Summaries and Data Return	0286-0000-24-672-L04-P	Knowledge	
374	Updated Status of Multiregional Clinical Trials Based on ICH E17 Guideline: 5 Years After the Implementation	0286-0000-24-673-L04-P	Knowledge	
375	Sustainability of Rare Disease Drug Development	0286-0000-24-674-L04-P	Knowledge	
375.1	Middle East Emerging Opportunities	0286-0000-24-694-L04-P		
376	Challenges in Quality Control for Cell and Gene Therapy Development: Regulatory Perspectives and Best Practices	0286-0000-24-675-L04-P	Knowledge	
377	Industry and Regulatory Experience in Implementing The E9(R1) Estimand Framework	0286-0000-24-676-L04-P	Knowledge	
401	Harnessing Real-World Data to Generate Real-World Evidence for Regulatory Grade Safety Studies	0286-0000-24-677-L04-P	Knowledge	
402	Harnessing Generative AI to Translate Questions into Insights	0286-0000-24-678-L04-P	Knowledge	
403	Achieving Diversity in Clinical Research Using Digital Health Technologies	0286-0000-24-679-L04-P	Application	
404	Meeting in the Middle: Best Practices for Collaboration Between Medical Affairs and Clinical Development	0286-0000-24-680-L04-P	Application	
405	The FDA's Commitment to Patient-Centric Research: Key Themes from Decentralized Trial Draft Guidance	0286-0000-24-681-L04-P	Knowledge	
406	More Nuanced Clinical Outcomes from Person-Generated Health Data: The New Frontier	0286-0000-24-682-L04-P	Knowledge	
407	Leveraging Statistical Approaches in Drug Safety Analysis	0286-0000-24-683-L04-P	Knowledge	

408	Targeting Hope for Oncology Patients: Perceptions and Considerations for Genetic Testing and Precision Medicine	0286-0000-24-684-L04-P	Knowledge	
410	The Impact of Racial Discrimination on the Patient Clinical Trial Experience	0286-0000-24-685-L04-P	Knowledge	
411	Generative AI-Driven Clinical Data Management: A Myth or a Reality?	0286-0000-24-686-L04-P	Knowledge	
412	Unleashing Biopharma Potential: Maximizing Consortia Engagement with Strategic Change Management	0286-0000-24-687-L04-P	Knowledge	21664WZFGG
413	What is the Value of Reference Agency Assessment Reports in Enabling Reliance and What do Relying Agencies Require?	0286-0000-24-688-L04-P	Knowledge	
414	Regulatory Affairs of the Future: Is Now	0286-0000-24-689-L04-P	Knowledge	
415	EMA-FDA Question Time	0286-0000-24-690-L04-P	Knowledge	
416	FDA Town Hall	0286-0000-24-691-L04-P	Knowledge	